CreaGen

Leader in Chemistry and drug discovery Contract Research services

Capability Slides









CREAGENING

CreaGen Inc.

- Premier Synthetic Organic and Medicinal Chemistry Contract Research Organization
- 10 years of experience in collaborating with Federal agencies: NIAID, NIDDK, NCATS, and DOD
- 20 years of experience in collaborating with Pharmaceutical and Biotechnology Companies: Astrazeneca, Abbvie, Medimmune, Novartis
- Over 70 years of collective personnel experience in drug discovery contract research



CreaGen Corporate Data

Address: 299 Washington St Woburn, MA

State of Incorporation: MA: Corporation Type: S Corporation

UEI: TR7EMJYU1KL9

CAGE: 4TEG8: MPIN: Creagen48

SBA Certification: 8(a)/Small Disadvantaged Business

NAICS CODES: 541715 (primary) - Research and Development in the Physical,

Engineering, and Life Sciences (except Nanotechnology and Biotechnology).

Contact Name:

Raj Rajur PhD, Founder and CEO CreaGen Inc.,

299 Washington Street, Woburn, MA 01801

Email: rrajur@creagenbio.com Phone: 781-938-1122 Ex: 1122 (O)

Mobile: 978-764-7068, Fax: 781-938-1122



Differentiators: Value Proposition

- Core expertise in Synthetic Organic Chemistry, Medicinal Chemistry and compound synthesis and purification.
- CreaGen has an established track record with Federal, biotech and pharmaceutical Laboratories
- Interdisciplinary strengths at CreaGen ensure that customers receive the best value for their investments

CreaGen's Competitive Advantage:

- Flexibility, competitive pricing and fast turnaround time
- US based contract research organization. IP protection is guaranteed

Therapeutic Area Expertise:

 Anti-infectives, Oncology, Metabolic diseases, Diabetes, CNS, and Cardiovascular



Past Performance Experiences

A: Contracting Organization: NIH/NIAID: Prime Contract

- Contract award number: 75N93019R00021
- Contract Type: IDIQ: Total Contract: Status: Ongoing contract
- Description of the requirement: 7-year Contract, Synthesis of Therapeutic Agents for the Treatment of Infectious Diseases (Task Area B).

B: Contracting Organization: DOD: Prime Contract

- Contract award number: W81XWH22D0016
- Contract Type: IDIQ: Status: Ongoing contract
- Description of the requirement: Five-year IDIQ contract recently awarded to CreaGen to synthesize Small Molecule inhibitors for U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

C: Contracting Organization: NIDDK:

- Contract award number: 75N94023P00560
- Contract Type: Purchase Order : Status: Ongoing Contract
- Description of the requirement: Synthesis of bioactive compound library



Past Performance Experience

C: Contracting Organization: NCATS:

- Contract award number: 75N95C22P00092
- Contract Type: Purchase order: Status: Completed
- Description of the requirement: Synthesis of Ter-Butyl Compound

D: Contracting Organization: CDC:

- Contract award number: 75D30121P10029
- Contract Type: Purchase Order: Status: Completed
- Description of the requirement: Synthesis of Aflatoxin Analog

E: Contracting Organization: DOD:

- Contract award number: W911QX19P0215
- Contract Type: Purchase Order: Status: Completed
- Description of the requirement: synthesis of 9 chemical compounds

F: Contracting Organization: NCATS:

- Contract award number: HHSN268201000263P
- Contract Type: Purchase Order: Status: Completed
- Description of the requirement: synthesis of lead compound



Our Partners













































Team

- Raj (SB) Rajur, PhD, Founder & CEO
 - 30 Years of academic, industrial and management experience: ArQule, Millipore, Boston College, Northeastern University, Massachusetts General Hospital and Harvard Medical School
- Hwa-OK Kim, PhD, Sr. Director of Chemistry
 30 Years of industrial and management experience: Aurigene Discovery Technologies, Molecumetics, Marion Merrell Dow and New Mexico State University
- David Barnes PhD, Director of R&D and External Alliances,
 25 Years of industrial and project management experience: Novartis Institute of Biomedical Research. Harvard University.
- Norton P. Peet, PhD, Chair, SAB
 30 Years of industrial and management experience: Aurigene Discovery Technologies, ArQule, Aventis, Marion Merrell Dow, University of Nebraska and MIT
- Robert Perni, PhD, Member, SAB
 35 Years of industrial and management experience: Sirtris Pharmaceuticals, Vertex Pharmaceuticals, Sterling Winthrop and Dartmouth College
- Mark Tebbe, PhD, Member, SAB
 30 Years of industrial and management experience: Atlas Ventures, Quench Bio, Forma Therapeutics, Eli Lilly, University of Notre Dame



Resources

- Established in 2003
- Corporate Headquarters: 299 Washington Street, Woburn, MA
- Scientists: Twenty-Five experienced team members, many with more than ten years in the pharmaceutical industry
- Existing laboratories: ~ 25,000 sq feet: newly expanded in January 2018
- Equipment: Waters LC-MS, Varian NMR (300 MHz), Waters auto purification system, Agilent analytical and Preparative HPLCs, Isco Combi-flash systems, TCAMs for parallel synthesis, Microwave synthesizer, Genevac evaporators, SFC Chiral Chromatography
- Library accessibility: online journal subscription, SciFinder and Beilstein/Crossfire access
- Laboratory recording: Perkin Elmer ELN Software



CreaGen Infrastructure & Equipment



Synthesis workstations: cont'd



Lyophilizer



CombiFlash RF 200



High speed evaporator GeneVac (EZ2)



Liquid Handler



CreaGen purification workstations





Mass directed purification

Chiral purification: SFC



CreaGen analytical workstations



Varian, 300 MHz NMR



TQ-LCMS



Summary

- Leader in Chemistry and Drug Discovery Contract Research and manufacturing Services
- Excellent past performance experience with Federal agencies (HHS, DOD)
- Excellent communication with collaborators
- Quality services and on-time delivery



Contact

Raj Rajur PhD, Founder and CEO

299 Washington Street, Woburn, MA 01801

Email: rrajur@creagenbio.com; Phone: 781-938-1122 Ex: 1122 (O)

Mobile: 978-764-7068, Fax: 781-938-1122

Anny Chum, Executive Director of administrations anny@creagenbio.com
781-938-1122

www.creageninc.com

